Clinical Trials Directory

Trials / Completed

CompletedNCT02097589

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
33 (actual)
Sponsor
University of Florida · Academic / Other
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

The purpose of this research study is to: Improve the effectiveness of vaccinations by identifying the effect of cholesterol medication, statins, on immune responses.

Detailed description

Due to the anti-inflammatory action of statins, it was proposed that statin treatment would decrease the efficacy of vaccination. This response has yet to be explored following a primary vaccination such as pneumococcal pneumonia. In this study, healthy volunteers will be divided into 2 arms receiving treatment for 28 days: 40 mg atorvastatin or placebo. Antibody titer for 23 serotypes, complete blood count (CBC), high-sensitivity c-reactive protein (hsCRP), erythrocyte sedimentation rate (ESR), lipids, cytokines (TNF-alpha, IFN-gamma, interleukins, etc.) and key membrane receptors (toll-like receptors, etc.) will be measured for baseline before statin or placebo treatment. On day 7 of treatment, pre-vaccination measures of the above parameters will be taken and an immune response will be induced in all groups using Pneumovax 23 at Day 7. On days 8, 14, 21, and 28 post-vaccination measures will be compared to baseline and between groups.

Conditions

Interventions

TypeNameDescription
DRUGAtorvastatin10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.
DRUGPneumovax 23Pneumovax 23 injected once, intramuscularly at Day 7.
OTHERPlacebo (lactose pill)10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.

Timeline

Start date
2014-06-01
Primary completion
2014-09-01
Completion
2014-09-01
First posted
2014-03-27
Last updated
2015-09-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02097589. Inclusion in this directory is not an endorsement.